Kangpu Biopharmaceuticals Received IND Approval from NMPA for KPG-818 to Treat Relapsed/Refractory Multiple Myeloma
Kangpu Biopharmaceuticals, Ltd. ("Kangpu") today announced that the Company has received IND approval from the CDE (Center ...
Auron Therapeutics Announces AUTX-703 Granted Fast Track Designation by the FDA for Relapsed or Refractory Acute Myelogenous Leukemia
AUTX-703 is a novel, first-in-class, oral KAT2A/B degrader discovered and developed by Auron using its AURIGIN™ Platform. The Company has previously presented preclinical data supporting the ability ...
AN2 Provides Strategic Update for Phase 3 EBO-301 Trial in Treatment Refractory MAC Lung Disease
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule ...
Cure Today17h
FDA Grants Fast Track Designation to AUTX-703 In R/R AML
The Food and Drug Administration granted fast track designation to AUTX-703 for relapsed or refractory acute myelogenous ...
Cure Today6d
The FDA Grants ODD to OPN-6602 For Relapsed/Refractory Myeloma
The FDA has granted orphan drug designation to the oral agent OPN-6602 for the treatment of patients with relapsed or ...
Healio8d
Regimen may become new standard for relapsed/refractory diffuse large B-cell lymphoma
The addition of epcoritamab-bysp to standard chemotherapy significantly improved response and survival for patients with ...
The American Journal of Managed Care22h
Allogeneic vs Autologous CAR T-Cell Therapy Explained
Allogene Therapeutics published new long-term follow-up data on cemacabtagene ansegedleucel, showing the investigative ...
gut.bmj8d
Reparative immunological consequences of stem cell transplantation as a cellular therapy for refractory Crohn’s disease
Background Treatment strategies for Crohn’s disease (CD) suppress diverse inflammatory pathways but many patients remain ...